These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 29520435)

  • 1. A phase I trial of escalating doses of cixutumumab (IMC-A12) and sorafenib in the treatment of advanced hepatocellular carcinoma.
    El-Khoueiry AB; O'Donnell R; Semrad TJ; Mack P; Blanchard S; Bahary N; Jiang Y; Yen Y; Wright J; Chen H; Lenz HJ; Gandara DR
    Cancer Chemother Pharmacol; 2018 May; 81(5):957-963. PubMed ID: 29520435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II study of cixutumumab (IMC-A12, NSC742460) in advanced hepatocellular carcinoma.
    Abou-Alfa GK; Capanu M; O'Reilly EM; Ma J; Chou JF; Gansukh B; Shia J; Kalin M; Katz S; Abad L; Reidy-Lagunes DL; Kelsen DP; Chen HX; Saltz LB
    J Hepatol; 2014 Feb; 60(2):319-24. PubMed ID: 24045151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I/II study of erlotinib in combination with the anti-insulin-like growth factor-1 receptor monoclonal antibody IMC-A12 (cixutumumab) in patients with advanced non-small cell lung cancer.
    Weickhardt A; Doebele R; Oton A; Lettieri J; Maxson D; Reynolds M; Brown A; Jackson MK; Dy G; Adjei A; Fetterly G; Lu X; Franklin W; Varella-Garcia M; Hirsch FR; Wynes MW; Youssoufian H; Adjei A; Camidge DR
    J Thorac Oncol; 2012 Feb; 7(2):419-26. PubMed ID: 22237261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I Study of Lenalidomide and Sorafenib in Patients With Advanced Hepatocellular Carcinoma.
    Shahda S; Loehrer PJ; Clark RS; Spittler AJ; Althouse SK; Chiorean EG
    Oncologist; 2016 Jun; 21(6):664-5. PubMed ID: 27256874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM model.
    Chugh R; Griffith KA; Davis EJ; Thomas DG; Zavala JD; Metko G; Brockstein B; Undevia SD; Stadler WM; Schuetze SM
    Ann Oncol; 2015 Jul; 26(7):1459-64. PubMed ID: 25858498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Prevalence and Impact of Hyperglycemia and Hyperlipidemia in Patients With Advanced Cancer Receiving Combination Treatment With the Mammalian Target of Rapamycin Inhibitor Temsirolimus and Insulin Growth Factor-Receptor Antibody Cixutumumab.
    Busaidy NL; LoRusso P; Lawhorn K; Hess KR; Habra MA; Fu S; Hong DS; Chen HX; Doyle LA; Kurzrock R; Naing A
    Oncologist; 2015 Jul; 20(7):737-41. PubMed ID: 26054632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multicentre, open-label, phase-I/randomised phase-II study to evaluate safety, pharmacokinetics, and efficacy of nintedanib vs. sorafenib in European patients with advanced hepatocellular carcinoma.
    Palmer DH; Ma YT; Peck-Radosavljevic M; Ross P; Graham J; Fartoux L; Deptala A; Studeny M; Schnell D; Hocke J; Loembé AB; Meyer T
    Br J Cancer; 2018 May; 118(9):1162-1168. PubMed ID: 29563636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma.
    Finn RS; Poon RT; Yau T; Klümpen HJ; Chen LT; Kang YK; Kim TY; Gomez-Martin C; Rodriguez-Lope C; Kunz T; Paquet T; Brandt U; Sellami D; Bruix J
    J Hepatol; 2013 Dec; 59(6):1271-7. PubMed ID: 23928403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I and Preliminary Phase II Study of TRC105 in Combination with Sorafenib in Hepatocellular Carcinoma.
    Duffy AG; Ma C; Ulahannan SV; Rahma OE; Makarova-Rusher O; Cao L; Yu Y; Kleiner DE; Trepel J; Lee MJ; Tomita Y; Steinberg SM; Heller T; Turkbey B; Choyke PL; Peer CJ; Figg WD; Wood BJ; Greten TF
    Clin Cancer Res; 2017 Aug; 23(16):4633-4641. PubMed ID: 28465443
    [No Abstract]   [Full Text] [Related]  

  • 10. Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial.
    Kudo M; Ueshima K; Yokosuka O; Ogasawara S; Obi S; Izumi N; Aikata H; Nagano H; Hatano E; Sasaki Y; Hino K; Kumada T; Yamamoto K; Imai Y; Iwadou S; Ogawa C; Okusaka T; Kanai F; Akazawa K; Yoshimura KI; Johnson P; Arai Y;
    Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):424-432. PubMed ID: 29631810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC).
    Tai WM; Yong WP; Lim C; Low LS; Tham CK; Koh TS; Ng QS; Wang WW; Wang LZ; Hartano S; Thng CH; Huynh H; Lim KT; Toh HC; Goh BC; Choo SP
    Ann Oncol; 2016 Dec; 27(12):2210-2215. PubMed ID: 27681866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Significance of VEGF and HIF-1 α in Hepatocellular Carcinoma Patients Receiving Sorafenib Versus Metformin Sorafenib Combination.
    El Shorbagy S; abuTaleb F; Labib HA; Ebian H; Harb OA; Mohammed MS; Rashied HA; Elbana KA; Haggag R
    J Gastrointest Cancer; 2021 Mar; 52(1):269-279. PubMed ID: 32212089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase II and Biomarker Study of Sorafenib Combined with Modified FOLFOX in Patients with Advanced Hepatocellular Carcinoma.
    Goyal L; Zheng H; Abrams TA; Miksad R; Bullock AJ; Allen JN; Yurgelun MB; Clark JW; Kambadakone A; Muzikansky A; Knowles M; Galway A; Afflitto AJ; Dinicola CF; Regan E; Hato T; Mamessier E; Shigeta K; Jain RK; Duda DG; Zhu AX
    Clin Cancer Res; 2019 Jan; 25(1):80-89. PubMed ID: 30190369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma.
    Abou-Alfa GK; Lau G; Kudo M; Chan SL; Kelley RK; Furuse J; Sukeepaisarnjaroen W; Kang YK; Van Dao T; De Toni EN; Rimassa L; Breder V; Vasilyev A; Heurgué A; Tam VC; Mody K; Thungappa SC; Ostapenko Y; Yau T; Azevedo S; Varela M; Cheng AL; Qin S; Galle PR; Ali S; Marcovitz M; Makowsky M; He P; Kurland JF; Negro A; Sangro B
    NEJM Evid; 2022 Aug; 1(8):EVIDoa2100070. PubMed ID: 38319892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.
    Zhu AX; Finn RS; Edeline J; Cattan S; Ogasawara S; Palmer D; Verslype C; Zagonel V; Fartoux L; Vogel A; Sarker D; Verset G; Chan SL; Knox J; Daniele B; Webber AL; Ebbinghaus SW; Ma J; Siegel AB; Cheng AL; Kudo M;
    Lancet Oncol; 2018 Jul; 19(7):940-952. PubMed ID: 29875066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety, tolerability, and pharmacokinetics of single and multiple doses of intravenous cixutumumab (IMC-A12), an inhibitor of the insulin-like growth factor-I receptor, administered weekly or every 2 weeks in patients with advanced solid tumors.
    Higano CS; Berlin J; Gordon M; LoRusso P; Tang S; Dontabhaktuni A; Schwartz JD; Cosaert J; Mehnert JM
    Invest New Drugs; 2015 Apr; 33(2):450-62. PubMed ID: 25749986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma after disease progression on sorafenib.
    El Dika I; Capanu M; Chou JF; Harding JJ; Ly M; Hrabovsky AD; Do RKG; Shia J; Millang B; Ma J; O'Reilly EM; Abou-Alfa GK
    Cancer Med; 2020 Oct; 9(20):7453-7459. PubMed ID: 32841541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I Study of Sorafenib and Vorinostat in Advanced Hepatocellular Carcinoma.
    Gordon SW; McGuire WP; Shafer DA; Sterling RK; Lee HM; Matherly SC; Roberts JD; Bose P; Tombes MB; Shrader EE; Ryan AA; Kmieciak M; Nguyen T; Deng X; Bandyopadhyay D; Dent P; Poklepovic AS
    Am J Clin Oncol; 2019 Aug; 42(8):649-654. PubMed ID: 31305287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates.
    Kelley RK; Nimeiri HS; Munster PN; Vergo MT; Huang Y; Li CM; Hwang J; Mulcahy MF; Yeh BM; Kuhn P; Luttgen MS; Grabowsky JA; Stucky-Marshall L; Korn WM; Ko AH; Bergsland EK; Benson AB; Venook AP
    Ann Oncol; 2013 Jul; 24(7):1900-1907. PubMed ID: 23519998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer.
    Ma CX; Suman VJ; Goetz M; Haluska P; Moynihan T; Nanda R; Olopade O; Pluard T; Guo Z; Chen HX; Erlichman C; Ellis MJ; Fleming GF
    Breast Cancer Res Treat; 2013 May; 139(1):145-53. PubMed ID: 23605083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.